Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
67°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2025
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
4D Molecular Therapeutics, Inc. - Common Stock
(NQ:
FDMT
)
6.810
-0.260 (-3.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 4D Molecular Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
May 01, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces New Employment Inducement Grants
April 11, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
March 27, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics
March 03, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts
February 10, 2025
Via
Benzinga
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
March 10, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
February 28, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
February 19, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts
January 13, 2025
Via
Benzinga
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics
December 18, 2024
Via
Benzinga
Analyst Expectations For 4D Molecular Therapeutics's Future
November 14, 2024
Via
Benzinga
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
February 10, 2025
4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.
Via
Benzinga
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
February 08, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
January 29, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
The Latest Analyst Ratings For 4D Molecular Therapeutics
September 09, 2024
Via
Benzinga
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
January 10, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
January 10, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday
December 18, 2024
Via
Benzinga
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
December 16, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
November 14, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
November 13, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
September 23, 2024
Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
September 19, 2024
4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to...
Via
Benzinga
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
September 18, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm
September 17, 2024
From
Kaskela Law LLC
Via
Business Wire
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
September 12, 2024
From
The Schall Law Firm
Via
Business Wire
4DMT Announces Presentations at Upcoming Retina Conferences
September 05, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
September 03, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
August 27, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 12, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
